Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

clinical trial

Wikidata entity: Q62024879



Quantities

P2899minimum age18
P1132number of participants72

P6099 clinical trial phase ... Q5452194 (phase I clinical trial) phase I clinical trial
P582 end time ... 2022-10-31 ???
P31 instance of ... Q30612 (clinical trial) clinical trial
P921 main subject ... Q187255 (rheumatoid arthritis) rheumatoid arthritis
P921 main subject ... Q1477 (ulcerative colitis) ulcerative colitis
P921 main subject ... Q707816 (giant cell arteritis) giant cell arteritis
P921 main subject ... Q19000413 (non small cell lung cancer recurrent) non small cell lung cancer recurrent
P1050 medical condition ... Q8277 (multiple sclerosis) multiple sclerosis
P1050 medical condition ... Q140067 (sclerosis) sclerosis
P1050 medical condition ... Q170990 (arthritis) arthritis
P1050 medical condition ... Q1752891 (polymyalgia rheumatica) polymyalgia rheumatica
P1050 medical condition ... Q179945 (psoriasis) psoriasis
P1050 medical condition ... Q2453464 (colitis) colitis
P4844 research intervention ... Q7041828 (nivolumab) nivolumab
P6153 research site ... Q126412 (Massachusetts General Hospital) Massachusetts General Hospital
P6153 research site ... Q30279912 (Duke University Medical Center) Duke University Medical Center
P8005 research subject recruitment status ... Q76649708 (recruiting) recruiting
P580 start time ... 2018-10-31 ???
P8363 study type ... Q78089383 (interventional study) interventional study
P1476 title Monolingualtext Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease ???

External Ids
P3098ClinicalTrials.gov IDNCT03656627

Why not click here or view trends?

log id: 4223170